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The  serum  procalcitonin  (PCT)  concentration  reﬂects  both  the  systemic  response  to bacterial  infection  and
its severity.  However,  its  accuracy  in distinguishing  intensive  care  unit  (ICU)  patients  with  and  without
infection  remains  low  owing  to a lack  of  speciﬁcity  and  the time  lapse  between  infection  onset  and
the  PCT  rise.  Hence,  PCT  cannot  be used  as  a marker  to  start  or  withhold  antibiotic  therapy  for  ICU
patients.  However,  the kinetics  of the  PCT  concentration  decrease  under  antibiotic  therapy  can  adequately
monitor  infection  evolution  with  therapy  and  can  help  to customise  antibiotic  duration.  PCT-guided
algorithms  to guide  antibiotic  discontinuation  were  able  to shorten  antibiotic  duration  without  impacting
patient  outcomes  in  several  multicentre  randomised  studies.  Notably,  antibiotics  can  be  stopped  very
early  when  PCT  is low  and  remains  low  as this  indicates  that  bacterial  infection  is unlikely. When  PCT
falls  to <0.5  ng/mL  or >80%  from  its  peak  value,  antibiotics  for non-localised  infections  can  safely  be
stopped.
ublis©  2015  The  Authors.  P
. Introduction
Increasing rates of drug-resistant bacteria have made antibiotic
tewardship a crucial issue in intensive care units (ICUs). Several
actors contribute to persistent antibiotic overuse in ICU patients:
he poor speciﬁcity of clinical signs to distinguish true bacterial
nfections from non-bacterial systemic inﬂammatory disorders; the
eed to treat all patients with suspected bacterial infection as early
s possible because of disease severity; and the need to use broad-
pectrum antibiotics, at least initially.
During the past decades, it was hypothesised that biomark-
rs could help to optimise in-ICU antibiotic therapy by better
dentifying patients with true bacterial infections requiring antibi-
tics, helping to stop antibiotics when bacterial infection becomes
nlikely and shortening antibiotic duration for patients evolving
avourably.To date, only a few biomarkers have been tested in large
nterventional trials, with procalcitonin (PCT) being the most stud-
ed. This review focuses on the potential contribution of PCT to
∗ Corresponding author at: Service de Réanimation Médicale, Institut de Cardi-
logie, Hôpital Pitié-Salpêtrière, Assistance Publique–Hôpitaux de Paris, Université
ierre-et-Marie-Curie, Paris 6, 47 boulevard de l’Hôpital, 75651 Paris Cedex 13,
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924-8579/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).hed  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
guide antibiotic consumption by ICU patients. Pertinently, PCT is
only moderately useful in detecting bacterial infections in ICU
patients. However, monitoring patients’ responses to antibiotics
with repeated PCT measurements contributed to shortening the
duration of antimicrobial administration in several randomised
studies.
2. Procalcitonin
PCT, the 116-amino acid peptide precursor of calcitonin, is nor-
mally synthesised by thyroid gland C-cells and is cleaved into
mature calcitonin, which plays a role in calcium homeostasis
[1,2]. Because PCT cleavage into calcitonin occurs before secretion,
circulating PCT is undetectable in normal subjects (<0.1 ng/mL).
However, systemic inﬂammation can trigger extrathyroidal non-
neuroendocrine calcitonin gene expression. In this context,
immature PCT is released into the bloodstream, whilst calcitonin
remains undetectable. Various cell types throughout the body con-
stitutively secrete PCT in response to various pro-inﬂammatory
signals such as endotoxin, interleukins-1 and -6, or tumour necro-
sis factor-alpha (TNF) [1–4]. Interferon-gamma (IFN), released
during viral infections, strongly downregulates this pathway [3].
PCT appears in the blood several hours after the inﬂammatory
insult, reaches its maximum at ca. 12 h and persists for several days
thereafter [5,6]. Importantly, the kinetics of PCT are not affected by
renal insufﬁciency or renal replacement therapy [7–9]. Elevated
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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CT levels are associated with different conditions responsible
or systemic inﬂammation and their severity, including trauma
10], severe burns [11], major surgery [12], particularly cardiac
urgery with cardiopulmonary bypass [13,14], post-resuscitation
yndrome [15,16], acute pancreatitis [17], acute graft rejection
18] and subarachnoid haemorrhage [19]. Moreover, PCT is highly
ensitive to bacterial infection, with signiﬁcantly higher levels
n infected compared with non-infected patients associated with
nfection severity [20–24]. The role of PCT during bacterial sepsis
emains elusive. In two experimental models of post-peritonitis
epsis, anti-PCT immunotherapy was able to lower the mortality
ate [6,25]. Because PCT injection had no effect in controls but was
ighly detrimental in infected animals [25], it was hypothesised
hat PCT could serve as a positive feedback during sepsis. Hence,
CT was proposed as a possible biomarker of bacterial infection.
. Procalcitonin as a diagnostic marker of bacterial
nfection
Notable overlap exists between clinical signs of bacterial
nfection and non-speciﬁc inﬂammation in ICU patients. Micro-
rganism isolation from sample cultures is the gold standard for
nfection diagnosis in these patients. However, waiting for labo-
atory results to decide whether or not to start antibiotics would
ntroduce a 24–48 h delay, potentially highly deleterious for the
atient [26]. It was postulated that PCT could help to better identify
CU patients with true bacterial infections.
For patients with community-acquired pneumonia, the serum
CT concentration is able differentiate bacterial from viral causes.
mong 545 patients with pneumonia symptoms consulting at the
mergency department (ED), 373 were classiﬁed as having true
acterial pneumonia, with an area under the receiver operating
haracteristics (AUROC) curve for PCT to predict bacterial pneu-
onia of 0.88. C-reactive protein (CRP) was slightly less efﬁcient
AUROC = 0.76). PCT > 0.1 ng/mL predicted bacterial pneumonia
ith 90% sensitivity and 59% speciﬁcity, whereas PCT > 1 ng/mL
id so with 43% sensitivity and 96% speciﬁcity [27]. For two large
ohorts of unselected febrile patients, the results were more equiv-
cal. The optimal PCT cut-off to detect bacterial infection was
.2–0.25 ng/mL, with 66–77% sensitivity and 59–68% speciﬁcity.
CT was as accurate as the ED physician’s judgement and CRP
28,29].
PCT levels in ICU patients have been widely studied to differenti-
te true bacterial sepsis from other forms of systemic inﬂammatory
esponse syndrome (SIRS). For a prospective cohort of 78 patients
ith SIRS symptoms admitted to the ICU, including 60 with subse-
uently conﬁrmed bacterial infection, a PCT threshold of 1.1 ng/mL
redicted bacterial infection with 97% sensitivity but only 78%
peciﬁcity [20]. PCT concentrations of another cohort of 101 unse-
ected patients with SIRS symptoms were associated with infection
everity, and 1 ng/mL predicted bacterial infection with 89% sensi-
ivity and 94% speciﬁcity [21]. The three meta-analyses conducted
n this subject have yielded conﬂicting results [30–32]. The most
ecent one analysed 3244 patients included in 30 studies. Het-
rogeneity of the results among studies was very high (I2 = 96%).
he overall optimal PCT threshold of 1.1 ng/mL to detect bacterial
epsis gave a mean sensitivity of 77% [95% conﬁdence inter-
al (CI) 72–81%] and a mean speciﬁcity of 79% (95% CI 74–84%)
32].
Post-cardiotomy patients, who are at particularly high risk for
ostoperative infections and frequently develop postoperative SIRS
nd circulatory failure that can mimic  severe bacterial infection,
ave been the focus of particular interest. However, the accu-
acy of PCT to distinguish infected from non-infected patients in
his setting is poor [33]. Uncomplicated surgery and postoperativetimicrobial Agents 46 (2015) S19–S24
circulatory failure increase serum PCT level. Whilst infected
patients have globally elevated circulating PCT levels compared
with non-infected patients, optimal thresholds varied widely from
one study to another, with PCT sensitivity to detect infection ran-
ging from 82% to 86% and speciﬁcity from 45% to 98%. Importantly,
PCT did not rise during compartmentalised infections such as medi-
astinitis [13].
The potential ability of PCT to detect infected necrosis following
severe pancreatitis has also been studied extensively. A meta-
analysis of the pooled results of seven observational studies [22]
highlighted that optimal PCT cut-offs across the studies ranged
widely (0.4–3.5 ng/mL), with a pooled sensitivity for PCT to detect
infected necrosis of 80% (95% CI 71–88%) and a pooled speciﬁcity of
91% (95% CI 87–94%). Thus, although PCT is associated with infected
necrosis, its accuracy as a diagnostic marker remains too low to
guide clinical decisions.
Ventilator-associated pneumonia (VAP) is the most frequent
nosocomial infection in mechanically ventilated patients, respon-
sible for high antibiotic consumption [34]. To date, the several
studies that investigated the potential contribution of PCT to diag-
nosing VAP have yielded disappointing results. In two studies on,
respectively, 148 and 57 mechanically ventilated patients sus-
pected of having VAP, serum and bronchoalveolar lavage PCT levels
did not differ between infected and non-infected patients [35,36].
In two other studies including, respectively, 73 and 96 patients,
PCT was  signiﬁcantly higher in patients with conﬁrmed VAP and
was strongly associated with their outcomes, but its crude accu-
racy to detect pneumonia was  very low: AUROC = 0.51 and 0.79
[23,24]. For another 44 patients [37], combining PCT with the Clin-
ical Pulmonary Infection Score increased VAP diagnostic speciﬁcity
to 100% but their combined sensitivity was only 67%. Because PCT
rises during the ﬁrst 24 h of infection, two  studies tested PCT con-
centration kinetics to diagnose VAP. The PCT AUROC to detect VAP
rose from 0.80 to 0.89 when D −1 to D0 levels were considered, and
fell to 0.62 when D0 to D1 levels were analysed [23,38]. However,
daily PCT monitoring is not feasible in routine clinical practice, and
its variations after suspected VAP have no advantage over bacterial
cultures, which remains the gold standard for diagnosis. Lastly, PCT
was used to detect bacterial co-infections in 46 patients infected
with H1N1 inﬂuenza virus. Here again, PCT was elevated in infected
patients but its diagnostic accuracy remained low (AUROC = 0.72)
[39].
Importantly, only a few studies have focused on the use-
fulness of PCT in identifying infection in immunocompromised
patients. For 107 immunocompromised patients with suspected
pulmonary infections referred for bronchoscopy, the PCT AUROC
to predict bacterial infection was  quite low (0.75) [40]. Among 119
immunocompromised ICU patients, PCT was signiﬁcantly elevated
in those with bacterial sepsis, predicting bacterial infection with
AUROC = 0.85. A 0.5 ng/mL threshold predicted bacterial sepsis with
100% sensitivity but only 63% speciﬁcity [41].
Thus, although PCT is associated with bacterial infections in
ICU patients, its diagnostic accuracy as a biomarker remains inad-
equate. Several factors may  explain this poor performance. First,
PCT increases with a 24–48 h time lag after infection onset, which
reduces the effectiveness of crude PCT measured when infection is
suspected. Second, PCT remains elevated for up to several weeks
after infection onset. Because ICU patients may  be subjected to
several bacterial insults during their ICU stay, PCT might still be
elevated due to previous episodes, thereby lowering its speciﬁcity
to detect a new infection. Third, PCT does not rise during localised
infections, even severe, such as mediastinitis or abscesses. Lastly,
many conditions associated with ICU care (profound circulatory
failure, major surgery, trauma, pancreatitis, etc.) trigger systemic
release of inﬂammatory mediators responsible for non-speciﬁc PCT
increase.
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. Procalcitonin to guide antibiotic initiation in ICU
atients
Because PCT is associated with bacterial infection and its sever-
ty [21,23,42,43], it has been postulated that PCT might be a reliable
ool to decide whether or not to treat a patient for a suspected
nfection.
PCT-guided initiation of antibiotics achieved a drastic reduction
n antibiotic consumption by patients with community-acquired
ower respiratory tract infections (LRTIs) without affecting hos-
ital mortality or morbidity in six large randomised studies [44].
n particular, for 243 patients consulting at the ED for symptoms
ompatible with LRTI, combining clinical judgement and an algo-
ithm that discouraged antibiotics when PCT was <0.25 g/L and
trongly discouraged them when it was <0.1 g/L decreased antibi-
tic use by up to 50% and yielded comparable clinical and laboratory
utcomes [45].
Such algorithms for ICU patients have been tested in two  ran-
omised studies to date. PRORATA, a large multicentre randomised
rial, tested the usefulness of a PCT-based algorithm (Fig. 1) to
uide antibiotic initiation, continuation and termination for 630
nselected ICU patients [46]. When the ﬁrst PCT determination
as <0.5 ng/mL, antibiotics were discouraged. Notably, the initial
ntibiotic prescription rate (almost 90%) did not differ between
CT-guided and control groups. Of 307 patients in the PCT group, 65
21.2%) received antibiotics despite PCT < 0.5 ng/mL. Another mul-
icentre randomised trial tested the use of a PCT-guided algorithm
or 509 ICU patients suspected of developing a bacterial infec-
ion. Antibiotics were again discouraged when the ﬁrst PCT was
0.5 ng/mL. That strategy did not achieve less antibiotic consump-
ion and only 46% of patients with low PCT levels were not treated
47].
This reluctance of physicians to base antibiotic initiation on
CT-guided algorithms for severely ill patients is explained by the
ig. 1. Procalcitonin-based algorithm used in the PRORATA trial to initiate, pursue or d
reatment (e.g. septic shock, purulent meningitis).timicrobial Agents 46 (2015) S19–S24 S21
biomarker’s low accuracy to detect bacterial infection in these
patients. In light of the possible harmfulness of delaying antibiotics
for critically ill patients, it indeed seems that the crude PCT concen-
tration is not the reliable tool sought to guide antibiotic initiation
in the ICU.
5. Using procalcitonin concentration kinetics to stop
antibiotics
The duration of antibiotic administration is still largely based
on empirical rules. In a randomised study on VAP, an 8-day reg-
imen was  apparently as effective as a 15-day regimen despite
concerns about a possibly higher VAP relapse rate due to non-
fermenting Gram-negative bacilli [48]. PCT variation after starting
antibiotics appears to be more closely associated with outcome
than the initial crude PCT. Hence, the decrease in serum PCT
levels has been proposed to guide stopping antibiotics, allow-
ing their administration duration to become ‘customised’ for
each patient and episode. Using this strategy again dramatically
reduced antibiotic consumption by patients referred to the ED for
LRTIs. The meta-analysis of data for 4211 patients conﬁrmed that
implementing a PCT-based algorithm to prescribe antibiotics for
these patients was  responsible for shortening the mean antibi-
otic duration from 10 days to 7 days, with no impact on patient
outcomes [44].
PCT-guided antibiotic duration has been tested in ﬁve ran-
domised ICU studies to date (Table 1) [46,49–52]. Basing antibiotic
discontinuation on a PCT-guided algorithm was  ﬁrst compared
with standard care for 79 patients with severe sepsis or septic
shock (70% of pulmonary origin) [50]. Patients with non-fermenting
Gram-negative bacillus infections were excluded. Antibiotics were
stopped when the PCT level had decreased >90% from baseline, after
at least 3 days or 5 days on antibiotics depending on the initial
PCT level. For the PCT-guided group, the authors observed notable
iscontinue antibiotics [46]. * Excludes situations requiring immediate antibiotic
S22 N. Bréchot et al. / International Journal of Antimicrobial Agents 46 (2015) S19–S24
Table  1
Main characteristics of randomised trials conducted to test the usefulness of procalcitonin (PCT)-guided algorithms to stop antibiotics in adult ICU patients.
Reference Setting No. of patients 1st episode (no. of days of
treatment)a
28-Day antibiotic exposure 28-Day mortality (%)
PCT Control PCT Control PCT Control PCT Control
Stolz et al. [49] VAP 51 50 9 (5–16) 12 (7–18) 10 (6–16) 15 (10–23)* 16 24
Nobre  et al. [50] Severe sepsis or septic
shock (70% pneumonia)
39; 31b 40; 37b 6 (3–34);
6  (4–16)
9 (2–33);
10 (3–33)*
13 ± 9; 11 ± 8 15 ± 8; 14 ± 8* 20; 16 20; 16
Hochreiter et al. [51] Severe sepsis, surgical
patients
57 53 6 ± 2 8 ± 1* N/R N/R 26 26
Schroeder et al. [52] Severe sepsis, surgical
patients
14 13 7 ± 1 8 ± 1* N/R N/R 21 23
Bouadma et al. [46] Unselected ICU patients 307 314 6 ± 6 10 ± 7* 16 ± 8 14 ± 9 * 21 20
ICU, intensive care unit; VAP, ventilator-associated pneumonia; N/R, not reported.
a Values are the median (interquartile range) or mean ± standard deviation.
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* P < 0.05.
rends towards shorter antibiotic duration for the ﬁrst infectious
pisode and less antibiotic exposure. Both indices differed signiﬁ-
antly between the two groups in per-protocol analyses (Table 1).
CU mortality, primary infection relapse rate and length of hospi-
al stay were comparable, whilst the ICU stay in the experimental
roup was shortened by 2 days. Another PCT-based algorithm to
uide antibiotic discontinuation was tested in a multicentre ran-
omised study on 101 patients with a VAP episode [49]. Antibiotic
iscontinuation was encouraged when PCT had decreased >80%
rom baseline or was <0.5 ng/mL, and was discouraged otherwise.
he mean antibiotic duration declined signiﬁcantly from 13 days to
.5 days for the PCT-guided group, whilst mechanical ventilation-
ree days, 28-day mortality and length of hospital stay remained
nchanged. In another randomised study, Hochreiter et al. enrolled
10 surgical patients to receive PCT-guided therapy or standard 8-
ay antibiotic therapy [51]. Pneumonia and peritonitis accounted
or more than one-half of the infectious episodes. Antibiotics were
iscontinued when PCT was <1 ng/mL or had decreased by >35%
rom baseline and clinical signs of infection had resolved, after at
east 3 days of therapy. The mean antibiotic treatment duration
ecreased from 8 days to 6 days, and the length of ICU stay for the
CT-guided group was signiﬁcantly shortened from 18 days to 15
ays.
The largest study, the PRORATA trial, was conducted on 621
nselected ICU patients randomised to be treated according to a
CT-based strategy (Fig. 1) suggesting antibiotic start and stop, or
 conventional strategy based on clinical criteria and international
nd institutional guidelines [46]. Most (>90%) ICU patients had been
eferred for medical reasons, with pneumonia accounting for >70%
f infections in both groups and community-acquired and noso-
omial infections equally distributed. PCT levels in the PCT-based
roup were measured daily. Physicians were encouraged to stop
ntibiotics as of Day 3 when PCT had decreased >80% from its peak
evel or had fallen to <0.5 ng/mL. Importantly, the treating physician
ade the ﬁnal decision. PCT group patients had signiﬁcantly more
ays without antibiotics than those in the control group (14.3 ± 9.1
s. 11.6 ± 8.2 days; absolute difference 2.7 days, 95% CI 1.4–4.1;
 < 0.0001). Respective rates of PCT and control group mortality on
ay 28 (21.2% vs. 20.4%; absolute difference 0.8%, 90% CI −4.6 to 6.2)
nd Day 60 (30.0% vs. 26.1%; absolute difference 3.8%, 95% CI −2.1 to
.7), infection relapse (6.5% vs. 5.1%; P = 0.45), superinfection (34.5%
s. 30.9%; P = 0.29) and acquisition of multidrug-resistant bacte-
ia (17.9% vs. 16.6%; P = 0.67) were comparable. Hospital and ICU
tays also remained unaffected. Importantly, the shorter duration
f antibiotic administration was maintained in subgroup analyses,
egardless of disease severity or infection site, and mortality of PCT
nd non-PCT patients remained strikingly comparable across the
ubgroups.Results of seven randomised studies using a PCT-based algo-
rithm to guide in-ICU antibiotic discontinuation were pooled in
a meta-analysis (one study concerned newborns and another
addressed PCT-guided antibiotic discontinuation and the need for
re-intervention following abdominal surgery), resulting in 1131
patients [53]. The PCT-guided group had a shorter total antibiotic
duration (mean difference −4.19 days, 95% CI −4.98 to −3.39), with
minor heterogeneity among trials. PCT- and non-PCT group mor-
tality [odds ratio (OR) = 0.93, 95% CI 0.69–1.26], ICU stay (mean
difference −0.49 days, 95% CI −1.55 to 0.57) and relapse or per-
sistent infection (OR = 0.97, 95% CI 0.59–1.69) were comparable.
In their cost-effectiveness study based on average daily antibi-
otic treatment costing 384 Canadian dollars, Heyland et al. found
that PCT-guided therapy saved 470 Canadian dollars per episode
[54].
Brieﬂy, a PCT-based algorithm combined with clinical judge-
ment is apparently a safe and useful tool to guide antibiotic
discontinuation and shorten antibiotic duration for ICU patients.
Importantly, severely immunocompromised patients (bone mar-
row transplantation or profound neutropenia) were excluded from
these studies, as were infections requiring prolonged antibiotic
administration such as mediastinitis, endocarditis, Mycobacterium
tuberculosis infections, etc. Additional research data are needed
to better characterise the possible role of biomarkers to guide
antibiotic therapy for these populations. For infections due to non-
fermenting bacilli, which were too infrequent in earlier studies
to reliably address the safety of PCT-based antibiotic steward-
ship in this context, cautious application of PCT guidance is
still required. Respecting these limitations, we could recommend
stopping antibiotics for infected ICU patients whose PCT levels
decreased >80% from the peak value or fell to <0.5 ng/mL, even
after only 3 days of therapy. The safety of this strategy will be fur-
ther addressed in a large multicentre randomised trial, the Stop
Antibiotics on guidance of Procalcitonin Study (SAPS), which plans
to enrol 1816 patients [55].
6. Procalcitonin to escalate antibiotics
Notably, a strategy based on PCT concentration kinetics was  pro-
posed to detect unfavourable infection evolution under antibiotics
and to guide treatment escalation in the large, randomised, multi-
centre, Procalcitonin and Survival Study (PASS) [56]. In total, 1200
ICU patients were randomised to receive standard antibiotic guid-
ance or PCT-guided antimicrobial-spectrum escalation. Serum PCT
was measured daily after infection onset. ‘Alert PCT’, deﬁned as
PCT ≥ 1 ng/mL and <10% decrease from the previous day, served
as a signal indicating that the infection might be uncontrolled. On
‘alert PCT’ days, physicians collected culture samples from possible
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nfection sites and were encouraged to obtain diagnostic imaging,
nd then had to follow an algorithm to guide antibiotic escala-
ion. Adequate antibiotic treatment was initiated slightly earlier for
CT group patients with bloodstream infections (−0.1 days vs. 0.8
ays; P = 0.02), but the timing remained comparable for other infec-
ions. 28-Day mortality was comparable (31.5% vs. 32%; relative
isk = 0.98, 95% CI 0.83–1.16; P = 0.83), but the PCT group consumed
ore antibiotics (6 days vs. 4 days; P = 0.001) and had longer ICU
tays (6 days vs. 5 days; P = 0.004) and times on mechanical venti-
ation (+4.9%), dialysis and vasopressors.
. Conclusion
The serum PCT level reﬂects bacterial infection and the severity
f damage it induces. Its accuracy in detecting bacterial infections
n ICU patients remains poor owing to a lack of speciﬁcity and the
ime lag between infection onset and PCT rise. As a consequence,
he PCT concentration cannot be used as a marker to guide antibi-
tic initiation in the ICU. However, according to several multicentre
andomised studies, PCT kinetics, with the concentration declining
ith antibiotic therapy, can adequately monitor evolution under
herapy and have been proven to shorten antibiotic administration
ithout impacting patient outcomes. Antibiotics can be stopped
ery early when PCT is low and remains low, indicating unlikely
acterial infection. When the PCT concentration falls to <0.5 ng/mL
r >80% from the peak value, antibiotics for non-localised infections
an be safely discontinued.
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